Evidence map›Paper›PMID 34868396›Full record

ArticleDisease markers2021

Identification of SOX6 and SOX12 as Prognostic Biomarkers for Clear Cell Renal Cell Carcinoma: A Retrospective Study Based on TCGA Database.

Xiao Lyu, Xi Zhang, Li-Bin Sun, Xiao-Ming Cao, Xu-Hui Zhang

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Disease markers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Xiao LyuDepartment of Urology, The First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.ORCID https://orcid.org/0000-0002-7186-4573
Xi ZhangDepartment of Urological Surgery, Shanxi Medical University, Taiyuan, Shanxi, China.ORCID https://orcid.org/0000-0001-7933-430X
Li-Bin SunDepartment of Urology, The First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.ORCID https://orcid.org/0000-0002-7265-0454
Xiao-Ming CaoDepartment of Urology, The First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.ORCID https://orcid.org/0000-0003-4257-9228
Xu-Hui ZhangDepartment of Urology, The First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.ORCID https://orcid.org/0000-0001-7477-9211
Shanxi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe SOX gene family has been proven to display regulatory effects on numerous diseases, particularly in the malignant progression of neoplasms. However, the molecular functions and action mechanisms of SOX genes have not been clearly elucidated in clear cell renal cell carcinoma (ccRCC). We aimed to explore the expression status, prognostic values, clinical significances, and regulatory actions of SOX genes in ccRCC.

methodsRNA-sequence data and clinical information derived from The Cancer Genome Atlas (TCGA) database was used for this study. Dysregulated SOX genes between the normal group and ccRCC group were screened using the Wilcoxon signed-rank test. The Kaplan-Meier analysis and univariate Cox analysis methods were used to estimate the overall survival (OS) and disease-specific survival (DSS) differences between different groups. The independent prognostic factors were identified by the use of uni- and multivariate assays. Subsequently, the Wilcoxon signed-rank test or Kruskal-Wallis test and the chi-square test or Fisher exact probability methods were employed to explore the association between clinicopathological variables and SOX genes. Finally, CIBERSORT was applied to study the samples and examine the infiltration of immune cells between different groups.

resultsHerein, 12 dysregulated SOX genes in ccRCC were screened. Among them, two independent prognostic SOX genes (SOX6 and SOX12) were identified. Further investigation results showed that SOX6 and SOX12 were distinctly associated with clinicopathological features. Furthermore, functional enrichment analysis revealed that SOX6 and SOX12 were enriched in essential biological processes and signaling pathways. Finally, we found that the SOX6 and SOX12 expression levels were correlated with tumor-infiltrating immune cells (TIICs).

conclusionThe pooled analyses showed that SOX6 and SOX12 could serve as promising biomarkers and therapeutic targets of patients with ccRCC.

Indexed as

Databases, GeneticBiomarkers, TumorCarcinoma, Renal CellFemaleHumansKidney NeoplasmsMaleMiddle AgedPrognosisRetrospective StudiesSOXC Transcription FactorsSOXD Transcription FactorsBiomarkers, TumorSOX12 protein, humanSOX6 protein, humanSOXC Transcription FactorsSOXD Transcription Factors

Identifiers

PMID34868396
PMCPMC8642026
OpenAlexW3216628889

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.